Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2024-10-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于2022年限制性股票激励计划首次授予第二次及预留授予第一次解除限售暨上市公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the unlocking and listing of restricted shares under a 2022 restricted stock incentive plan. It details the approval and implementation of the stock incentive plan, the unlocking conditions being met, the number of shares unlocked, and the listing date. It includes specific dates, share quantities, and compliance with regulatory requirements. The document is not a full financial report, earnings release, or management discussion, but rather a formal announcement about stock incentive plan share unlock and listing. This fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about share unlock and listing under a stock incentive plan, not a full report or financial statement.
2024-10-21 Chinese
益丰药房关于2022年限制性股票激励计划预留授予第一个解除限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the unlocking of restricted stock under a 2022 restricted stock incentive plan. It details the number of shares unlocked, the conditions met for unlocking, the list of incentive recipients, and legal and supervisory opinions confirming compliance with relevant regulations. The document is not a full financial report, earnings release, or management discussion, but rather a formal disclosure about stock incentive plan execution and share unlocking. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share-based compensation and stock unlocking conditions, not a full report or financial statement. The document length is under 5,000 characters, and it is a detailed announcement rather than a report publication notice or certification letter.
2024-10-15 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司2022年限制性股票激励计划首次授予第二个解除限售期解除限售条件成就相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the achievement of conditions for the second unlocking period of a 2022 restricted stock incentive plan for a company. It details the legal procedures, conditions for lifting stock restrictions, performance assessments, and the number of shares and participants involved. It is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to a stock incentive plan. This type of document fits best under Regulatory Filings (RNS) as it is a legal compliance and disclosure document that does not fall under other specific categories like Remuneration Information or Capital/Financing Update. The document length and content confirm it is not a brief announcement or a full annual/interim report. Therefore, the classification is RNS with high confidence.
2024-10-15 Chinese
益丰药房关于控股股东及其一致行动人减持可转换公司债券的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the reduction in holdings of convertible bonds by the controlling shareholder and its concerted parties. It details the number of bonds held before and after the reduction, the dates of the transactions, and the regulatory approval for the bond issuance. There is no financial statement or comprehensive financial report content. The document is a formal disclosure of a transaction involving the company's own convertible bonds, specifically a reduction in holdings by insiders. This fits the category of a Transaction in Own Shares (POS), as it reports on the company-related insiders selling or reducing their holdings in convertible bonds issued by the company.
2024-10-15 Chinese
益丰药房关于调整2022年限制性股票激励计划部分限制性股票回购注销价格的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the adjustment of the repurchase and cancellation price of restricted stocks under the 2022 restricted stock incentive plan. It details board and supervisory meetings, legal opinions, and specific price adjustments for repurchased shares. The document is relatively short (2925 characters) and focuses on a specific corporate action related to stock repurchase and cancellation prices under an incentive plan. It does not contain comprehensive financial statements or detailed financial performance data. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a report publication announcement since it contains substantive content about the stock repurchase price adjustment. The content fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares, including repurchase and cancellation of restricted stock shares.
2024-10-15 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司调整2022年限制性股票激励计划回购注销价格的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the repurchase and cancellation price of restricted stock incentive plan shares for the year 2022 by a company. It discusses the legal compliance, approval process, and specific price adjustments related to the stock incentive plan. The document is not a financial report, earnings release, or regulatory filing but a standalone legal opinion related to a specific corporate action. This fits best under the category of Audit Report / Information (AR), which includes applied accounting principles and related legal or regulatory opinions that are not full annual reports. FY 2024
2024-10-15 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.